Irritable Bowel Syndrome: Boswellia as a promising alternative

approach to manage symptoms

A new study shows that supplementation with the lecithin-based delivery form of
Boswellia serrata can control symptoms of mild Irritable Bowel Syndrome.

Milan, July 13th, 2017 – A new supplement registry study[1] has shown that Casperome®,
the Indena Phytosome formulation of Boswellia serrata delivering the full natural bouquet
of triterpenoids, rapidly alleviates the symptoms of Irritable Bowel Syndrome (IBS).
The study enrolled 71 otherwise healthy subjects with idiopathic IBS that knowingly
decided to follow one of these management strategies: Hyoscine butylbromide,
administered when needed (Group 1); papaverine hydrochloride 10mg + belladonna
extract 10mg, administered when needed (Group 2); supplementation with Casperome®,1
tablet of 250 mg per day, for 4 weeks (Group 3). All groups were comparable in term of
age and gender distribution and they presented similar clinical characteristics at inclusion.
Abdominal pain, altered bowel movements, meteorism and cramps were evaluated by
subjects before the inclusion and during the last week before the end of the observational
period (4 weeks). Furthermore, conventional drugs were considered as rescue
medications in case Casperome® supplementation failed to alleviate IBS symptoms.
All IBS symptoms investigated improved during the period with the three management
strategies, but only in the Casperome®-supplemented group did the number of subjects
with any IBS symptoms significantly decrease, from 58% to 12.5%. Consistently, in
Casperome®-supplemented group, the number of subjects who needed medical attention
significantly decreased to 4.1%.
In addition, the prevalence of side effects was significantly higher in the two groups
treated with the Standard Management Strategies (28% for group 1 and 26% for
group 2) compared to Casperome® supplemented subjects (8.2%).
Irritable Bowel Syndrome (IBS) is a chronic, relapsing, gastrointestinal disorder in which
abdominal pain or discomfort is associated with defecation or change in bowel habits. It
affects 10-20% of the adult population and is often unrecognized or untreated. Considering
the chronic nature of this disorder, IBS has a strong negative impact on subjects’ work and
social life.
This study demonstrates that Casperome® supplementation may represent a promising
alternative approach to manage symptoms associated with IBS in otherwise healthy
subjects.

###

(Casperome_IBS_ENG_DEF)
 ®
CASPEROME is a purified extract rich in triterpenoid acids from the gum resin of Boswellia
serrata. Given the poor bioavailability of these compounds[2], Indena has formulated the extract
®
with Phytosome technology to optimize their absorption and further support their functions in
modulating physiological response to various challenges.
To know more about Casperome: www.casperome.info

Further info on Phytosomes: www.phytosomes.info

® ®
To know more about Phytosome technology watch the video “Phytosome :The technology
explained” on the Indena YouTube channel

Indena is the leading company dedicated to the identification, development and production of high
quality active principles derived from plants, for use in the pharmaceutical, health food and personal
care industries. Backed up by over 90 years of botanical experience, the company holds more than
120 primary patents, has published more than 700 scientific studies and co-operates with the
world’s most prestigious universities and private research institutions. Indena employs about 800
staff, investing around 10% of its annual turnover in research, making this activity the key to its
success. Headquartered in Milan, Indena has 5 production sites and 5 international branches
throughout the world and manages sales in more than 70 countries. The Company's experts
communicate and interact constantly with the major international regulatory authorities such as
WHO, EMA, FDA and ESCOP, and cooperate on the update of all the main pharmacopoeias.

Further information on Indena:www.indena.com

Follow us on Twitter: @IndenaSpA

Indena Press Contacts:

Cohn & Wolfe Milan
Laura Faravelli: laura.faravelli@cohnwolfe.com
Lorenzo Petracco: lorenzo.petracco@cohnwolfe.com
Tel. +39 02 202391

References:
[1] – Belcaro G, Gizzi G, Pellegrini L, Corsi M, Dugall M, Cacchio M, Feragalli B, Togni S, Riva A,
Eggenhoffner R, Giacomelli L. supplementation with a lecithin-based delivery form of Boswellia
®
serrata extract (Casperome ) controls symptoms of mild Irritable Bowel Syndrome.
[2] - Buechele B. et al. J Chromatogr B 2003; 795: 355-62.

Please note that the physiological activity of the ingredient described herein is supported by the referenced
clinical trial reports. Marketers of finished products containing the ingredient described herein are responsible
for determining whether the claims made for such products are lawful and in compliance with the laws of the
country in which they will market the products.
These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

(Casperome_IBS_ENG_DEF)